

**File No. 4-01/2013-DC (Misc. 13-PSC-Part-III)**  
**Govt. of India**  
**Directorate General of Health Services**  
**Central Drugs Standard Control Organization (India)**  
**(FDC Division)**

FDA Bhawan, Kotla Road  
New Delhi-110002

Dated: 12-04-2021


**PUBLIC NOTICE**

**Subject: Meeting of DTAB Sub Committee through WebEx (Video Conference) w.e.f. 19.04.2021 to 07.05.2021 for examining the Fixed Dose Combinations (FDCs) considered as irrational by Prof. Kokate Committee and to provide hearing to the stakeholders-regarding.**

This is in continuation to this Directorate Public Notice dated 23.03.2021 whereby, this office requested to submit the details and confirm the participation details of stakeholders by 09.04.2021. However, it has been observed that only a few applicants have submitted the requisite details.

You are therefore, once again requested to kindly confirm your participation through e-mail at [fcc@cdsco.nic.in](mailto:fcc@cdsco.nic.in) by 16.04.2021 and also submit PPT along with the presenter details, mobile number, e-mail, FDC identification No as per this Directorate Public Notice dated 23.03.2021. It may be noted that in the event that the applicant does not attend the hearing, the Sub-Committee reserves the right to make its decision on the basis of information available before it.

This is for information of all the concerned.



(Sanjeev Kumar)  
DDC(I), CDSCO (HQ) &  
Convener, Sub-Committee of DTAB

**Copy for necessary action to:**

1. Dr. Nilima Kshirsagar, Emeritus Scientist, former Chair in Clinical Pharmacology, Indian Council of Medical Research (ICMR), (Chairperson)
2. Indian Drugs Manufacturing Associations (IDMA/FOPE/CIPI/IPA) - with the request to communicate it to your members and publicize it widely so that all concerned can avail this opportunity.
3. Website of CDSCO for information and necessary action to all stakeholders.